GlassScriptPhysician profile
Michelle J Bailey
NPI 1841940673
$2,892.14
in general payments reported to CMS, 2019-2025
17 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $981 · 2024: $1,253 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $966.41 | 2023-2025 | |
| Novo Nordisk INC | $466.85 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $430.37 | 2022-2025 | Mounjaro, Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $240.91 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $119.03 | 2023-2025 | |
| Exact Sciences Corporation | $95.85 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $91.59 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.12 | 2022-2025 | Jardiance, Ofev, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.51 | 2024 | Xifaxan |
| Aurinia Pharma U.S., INC. | $59.66 | 2023-2024 | Lupkynis |
| Esperion Therapeutics, INC. | $56.27 | 2024-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $42.81 | 2025 | Spravato |
| Pfizer INC. | $42.43 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $38.06 | 2023-2024 | Livalo, Seglentis |
| Otsuka America Pharmaceutical, INC. | $37.82 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $17.19 | 2024 | Tymlos |
| Boston Scientific Corporation | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.